{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:46:40Z","timestamp":1792151200031,"version":"4.4.0"},"reference-count":29,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.18553\/jmcp.2026.26277","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:43:49Z","timestamp":1790181829000},"page":"1189-1200","source":"Crossref","is-referenced-by-count":0,"title":["Which drugs will Medicare negotiate next? Predicting selected drugs for Initial Price Applicability Year 2029"],"prefix":"10.18553","volume":"32","author":[{"given":"Kevin H.","family":"Li","sequence":"first","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma M.","family":"Cousin","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"Yarmuth JA. H.R.5376 - an act to provide for reconciliation pursuant to title II of S. Con. Res. 14.: 117th Congress (2021-2022). Congress.gov. August 16, 2022. Accessed June 16, 2026. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/5376"},{"key":"r2","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2026. 2024. Accessed June 16, 2026. https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf"},{"key":"r3","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2027. 2025. Accessed June 16, 2026. https:\/\/www.cms.gov\/files\/document\/factsheet-medicare-negotiation-selected-drug-list-ipay-2027.pdf"},{"key":"r4","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2028. 2026. Accessed June 16, 2026. https:\/\/www.cms.gov\/files\/document\/factsheet-medicare-negotiation-selected-drug-list-ipay-2028.pdf"},{"key":"r5","unstructured":"Centers for Medicare & Medicaid Services. Timeline: Medicare Drug Price Negotiation Program proposed rule (CMS-4215-P). 2026. Accessed June 16, 2026. https:\/\/www.cms.gov\/files\/document\/mdpnp-nprm-milestones.pdf"},{"key":"r6","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program: final guidance. Implementation of Sections 1191\u20131198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028. 2025. Accessed June 4, 2026. https:\/\/www.cms.gov\/files\/document\/ipay-2028-final-guidance.pdf"},{"key":"r7","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program proposed rule (CMS-4215-P). 2026. Accessed June 16, 2026. https:\/\/www.cms.gov\/files\/document\/mdpnp-nprm-fact-sheet.pdf-0"},{"key":"r8","unstructured":"Centers for Medicare & Medicaid Services. Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program.\n                      Federal Register\n                      . June 16, 2026. Accessed June 16, 2026. https:\/\/www.federalregister.gov\/documents\/2026\/06\/16\/2026-12059\/medicare-drug-price-negotiation-program-and-medicare-prescription-drug-benefit-program"},{"key":"r9","author":"Martin K","year":"2026","journal-title":"Health Affairs."},{"key":"r10","unstructured":"Arrington JC. H.R.1 \u2013 an act to provide for reconciliation pursuant to title II of H. Con. Res. 14.: 119th Congress (2025-2026). Congress.gov. July 4, 2025. Accessed June 16, 2026. https:\/\/www.congress.gov\/bill\/119th-congress\/house-bill\/1\/text"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.25253"},{"key":"r12","unstructured":"U.S. Food and Drug Administration. \u201cDeemed to be a License\u201d Provision of the BPCI Act. February 9, 2024. Accessed June 16, 2026. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/deemed-be-license-provision-bpci-act"},{"key":"r13","unstructured":"U.S. Bureau of Labor Statistics. CPI Inflation Calculator. Accessed June 18, 2026. https:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"key":"r14","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part D spending by drug. CMS Data. 2024. Accessed June 16, 2026. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-d-spending-by-drug\/data"},{"key":"r15","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part B spending by drug. CMS Data. 2024. Accessed June 16, 2026. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug\/data"},{"key":"r16","unstructured":"National Library of Medicine. RxNorm. National Institutes of Health. 2024. Accessed June 16, 2026. https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm\/index.html"},{"key":"r17","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed June 16, 2026. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"r18","unstructured":"U.S. Food and Drug Administration. Purple Book: database of licensed biological products. Accessed June 16, 2026. https:\/\/purplebooksearch.fda.gov\/"},{"key":"r19","unstructured":"U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Accessed June 16, 2026. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm"},{"key":"r20","unstructured":"U.S. Food and Drug Administration. Search Orphan Drug designations and approvals. Accessed June 16, 2026. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/"},{"key":"r21","unstructured":"Freed M, Biniek JF, Damico A, Ochieng N, Neuman T. Medicare Advantage in 2026: enrollment update and key trends. KFF. June 5, 2026. Accessed June 16, 2026. https:\/\/www.kff.org\/medicare\/medicare-advantage-in-2026-enrollment-update-and-key-trends\/"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.25199"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.3.229"},{"key":"r24","unstructured":"Celltrion.\n                      A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer\n                      . clinicaltrials.gov; 2025. Accessed July 4, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06939595"},{"key":"r25","unstructured":"Formycon. Formycon announces positive clinical data for Keytruda\n                      \u00ae\n                      biosimilar candidate FYB206 (pembrolizumab). February 25, 2026. Accessed July 4, 2026. https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-announces-positive-clinical-data-for-keytruda-biosimilar-candidate-fyb206-pembrolizumab\/"},{"key":"r26","unstructured":"Business Wire. Samsung Bioepis announces positive preliminary phase 1 and phase 3 data for SB27, a proposed biosimilar to Keytruda (pembrolizumab). June 29, 2026. Accessed July 4, 2026. https:\/\/www.businesswire.com\/news\/home\/20260629121432\/en\/Samsung-Bioepis-Announces-Positive-Preliminary-Phase-1-and-Phase-3-Data-for-SB27-a-Proposed-Biosimilar-to-Keytruda-Pembrolizumab"},{"key":"r27","unstructured":"Henlius. U.S. FDA clearance of IND for pembrolizumab biosimilar HLX17. September 9, 2025. Accessed July 4, 2026. https:\/\/www.henlius.com\/en\/NewsDetails-5443-26.html"},{"key":"r28","unstructured":"Hogan Lovells Cadwalader. CMS issues first proposed rule for the IRA\u2019s Drug Price Negotiation Program, for IPAY 2029 and beyond. June 18, 2026. Accessed July 13, 2026. https:\/\/www.hlc.com\/en\/publications\/cms-issues-first-proposed-rule-for-the-iras-drug-price-negotiation-program-for-ipay-2029-and-beyond"},{"issue":"11","key":"r29","first-page":"qxaf222","volume":"3","author":"Beinfeld MT","year":"2025","journal-title":"Health Aff Sch"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:52:33Z","timestamp":1792147953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.26277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.18553\/jmcp.2026.26277"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.26277","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}